Back to top
more

Aytu BioPharma, Inc. (AYTU)

(Delayed Data from NSDQ)

$2.31 USD

2.31
53,613

+0.21 (9.74%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.24 -0.07 (-3.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).

Sanghamitra Saha headshot

Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers

by Sanghamitra Saha

Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.

Zacks Equity Research

Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?

by Zacks Equity Research

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.

Zacks Equity Research

Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AYTU) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu

Zacks Equity Research

Sarepta Stock Up Almost 40% This Year So Far: Here's Why

by Zacks Equity Research

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

Nalak Das headshot

Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks

by Nalak Das

A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.

Zacks Equity Research

Myriad Genetics Announces Study Results Of myRisk Cancer Test

by Zacks Equity Research

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.